Of note, we show novel data indicating that NSC61610 may decrease inflammation by alternatively targeting the leukotriene A4 hydrolase, which is an enzyme linked to the production of inflammatory lipid mediators such as leukotrienes, suggesting a possible role of NSC61610 in modulating the synthesis of lipid mediators such as prostaglandins and leukotrienes that worsen the pathogenesis of IBD. Here, LTA4H is linked to inflammatory bowel disease.